The presence of a TP53 mutation was associated with longer OS in combination with KRASwt in patients treated with first-line chemoimmunotherapy (Supplementary Fig. 3), but not in patients with KRASmut NSCLC (Supplementary Figure 2). Here, TP53 is linked to non-small cell lung carcinoma.